Table 1.
Patient characteristics
| Patient no./sex/age | Disease | GVHD prophylaxis | GVHD staging (onset day) | GVHD treatment | Days after transplantation of sample collection(s) |
|---|---|---|---|---|---|
| 1/M/46 | ALL | T/M | a/cGVHD (44/151) | P/MSC/T | 53, 98, 190 |
| 2/F/42 | ALL | C/M | aGVHD(116) | C/T/P/MF/AT | 116 |
| 3/F/48 | AML | T/M | aGVHD (35) | T/P | 35, 72 |
| 4/F/46 | AML | T/M | a/cGVHD(18/231) | P | 125, 231, 348, 528 |
| 5/M/44 | CML | T/M | cGVHD(227) | T/P | 64, 227, 362, 721 |
| 6/F/56 | AML | T/M | No GVHD | NA | 90 |
| 7/F/53 | LGL | T/M | No GVHD | NA | 28, 92, 185, 368 |
| 8/F/49 | Myel | T/M | cGVHD (120) | P | 338, 437 |
| 9/F/69 | MDS | C/MF | cGVHD (187) | P | 94, 200, 340 |
| 10/F/53 | NHL | C/MF | cGVHD (158) | P | 157, 271 |
| 11/F/55 | AML | T/M | cGVHD (120) | P/T | 34, 84, 153 |
| 12/F/47 | AML | T/M | aGVHD (64) | T/P | 99, 175 |
| 13/F/50 | CML | T/M | No GVHD; relapse | NA | 36, 180, 193, 344, 513 |
| 14/F/41 | MDS | T/M | cGVHD(230) | P/T/PH | 46, 79, 178, 228 |
| 15/F/57 | CLL | C/MF | aGVHD (18) | P/C/MF | 37 |
| 16/F/30 | T-ALL | C/M/4 | aGVHD (11) | C/M/MF/AT/OK/R/Z | 58 |
| 17/M/53 | MDS | T/M | a/cGVHD (79/153) | P/T | 25, 79, 166, 362 |
| 18/M/40 | NHL | C/MF | cGVHD (171) | C/MF/P/T | 105 |
C indicates cyclosporine; M, methotrexate; T, tacrolimus; 4, CD4 peptide; MF, mycophenolate mofotil; AT, antithymocyte globulin; OK, OKT3 anti-CD3 antibody; R, rapamycin; Z, zenapax; P, prednisone; MSC, mesenchymal stem cells; aGVHD, acute GVHD; cGVHD, chronic GVHD; and PH, photopheresis.